As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out...
Pfizer
Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that...
Pfizer has pumped the brakes on six early-stage assets, including three being tested for ulcerative...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of...
Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at...
As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with...
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for...
Pfizer’s VC arm has backed a $100 million series A raise for OTR Therapeutics as...
After a chaotic and fierce bidding clash that only burst out into public view a...
For the second year running, Pfizer has arrived at the European Society for Medical Oncology...